Google Übersetzer
Savara Inc
About
Savara Inc (NASDAQ:SVRA) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 15 2026
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Apr 7 2026
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Mar 30 2026
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Mar 13 2026
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
Mar 6 2026
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Recent Videos
Wednesday, March 18, 2026 11AM UTC – Daily News: Zacks…
Mar 18, 2026
SAVARA STOCK : FRESH UPTREND | SVRA STOCK
Mar 15, 2026
Savara’s Stock Price is a Life-or-Death Metric
Feb 28, 2026
Savara’s FDA Rejection: What Biotech Investors Need to Know
Feb 24, 2026
Financials
Revenue
$1 K
Market Cap
$1.14 B
EPS
-0.53